Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.360 +2.190 (+52.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Kezar Life Sciences Shares Are Getting Hammered
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Kezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation Disease
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Insider Weekends: Return Of The Meme Stocks - GameStop (GME) And AMC Entertainment (AMC)
  
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Allego N.V. (NYSE: ALLG) shares surged 114.1% to close at $17.73 on Wednesday after the company announced the completion of its merger agreement with Spartan Acquisition... 
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allego N.V. (NYSE: ALLG) shares jumped 158.5% to $21.41 after the company announced the completion of its merger agreement with Spartan Acquisition Corp., which resulted... 
Via Benzinga
Here's Why Kezar Life Sciences Shares Are Moving
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher by 5.0% at $16.08 after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target... 
Via Benzinga
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Appoints Courtney Wallace to its Board of Directors
From Kezar Life Sciences
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG)... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 150 Points; Talkspace Shares Slide
Toward the end of trading Tuesday, the Dow traded up 0.42% to 36,239.46 while the NASDAQ rose 0.76% to 15,974.21. The S&P also rose, gaining 0.59% to 4,710.24. The U.S. has... 
Via Benzinga
Topics Stocks
Stocks Rise Amid Upbeat Consumer Strength Data
The Dow Jones Industrial Average is extending this morning's gains, up 189 points at last check, while the S&P 500 and Nasdaq Composite are also in the black midday. 
Via Talk Markets
Topics Stocks
Mid-Day Market Update: Crude Oil Down 1%; Kezar Life Sciences Shares Surge
Midway through trading Tuesday, the Dow traded up 0.25% to 36,176.74 while the NASDAQ rose 0.19% to 15,883.75. The S&P also rose, gaining 0.21% to 4,692.49. The U.S. has the... 
Via Benzinga
Topics Stocks
Why Kezar Life Sciences Stock Is Soaring Today
The company reported promising results from a phase 2 study. 
Via The Motley Fool
53 Stocks Moving In Tuesday's Mid-Day Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG) shares climbed 35.5% to... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Walmart Tops Q3 Expectations
Following the market opening Tuesday, the Dow traded up 0.40% to 36,231.05 while the NASDAQ rose 0.20% to 15,885.76. The S&P also rose, gaining 0.31% to 4,697.11. The U.S. has... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8... 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. 
Via InvestorPlace
36 Stocks Moving in Tuesday's Pre-Market Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:... 
Via Benzinga
Small-cap Biopharma Kezar Life Sciences Is Soaring, Here's Why
Kezar Life Sciences, Inc. (NASDAQ: KZR) shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.